Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Misoprostol + vasopressin is a combination of two pharmaceutical agents used primarily as hemostatic adjuncts during surgical procedures such as myomectomy. Misoprostol is a synthetic prostaglandin E1 analog that induces uterine contractions and promotes cervical ripening, while vasopressin is an endogenous antidiuretic hormone with potent vasoconstrictive properties. When used together, this combination has been shown to significantly reduce perioperative blood loss compared to either agent alone, particularly in gynecological surgeries involving fibroids[1][4]. Misoprostol acts by binding to prostaglandin E1 receptors on smooth muscle cells in the uterus, increasing contractility and reducing bleeding. Vasopressin exerts its effect by causing local vasoconstriction at the site of injection, thereby minimizing blood flow and hemorrhage risk[3][6]. This combination leverages both uterotonic and vasoconstrictive mechanisms for optimal hemostasis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on misoprostol + vasopressin.